Meine Lieblingsaktie schwächelt mal wieder - Chance zum Nachlegen - 500 Beiträge pro Seite
eröffnet am 14.07.05 11:12:14 von
neuester Beitrag 14.07.05 11:53:11 von
neuester Beitrag 14.07.05 11:53:11 von
Beiträge: 2
ID: 993.247
ID: 993.247
Aufrufe heute: 0
Gesamt: 627
Gesamt: 627
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 12:50 | 2607 | |
| vor 1 Stunde | 2294 | |
| heute 13:50 | 1438 | |
| vor 50 Minuten | 999 | |
| vor 24 Minuten | 996 | |
| vor 59 Minuten | 966 | |
| vor 31 Minuten | 935 | |
| vor 32 Minuten | 848 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.001,60 | +0,59 | 240 | |||
| 2. | 2. | 168,20 | +0,08 | 87 | |||
| 3. | 3. | 9,7000 | +12,27 | 75 | |||
| 4. | 14. | 6,1400 | -1,35 | 69 | |||
| 5. | 11. | 0,1865 | 0,00 | 52 | |||
| 6. | 7. | 0,8750 | -12,50 | 47 | |||
| 7. | 12. | 0,1561 | +2,97 | 38 | |||
| 8. | 6. | 2.302,50 | 0,00 | 36 |
FeedbackWarum ich glaube, daß diese Aktie HEISS ist, hab ich an anderer Stelle schon dargelegt Thread: cytogenix: ist das die wende?
Momentan keine neuen Fundamentals, also Chance zum billigen Nachlegen.
RAiDAR alerts Learn More About RAiDAR-LT
06/27/2005 (12:03 ET) Audiostocks.Com Interviews Leading Executives - PrimeZone Media Network
06/21/2005 (10:07 ET) CYGX:Announces Testing of Vaccine Against Smallpox - Knobias
06/21/2005 (10:05 ET) CytoGenix Announces Testing of Synthetic DNA Vaccine Against Smallpox - Business Wire
06/17/2005 (13:28 ET) CYGX: Filed New Form DEF 14A, Definitive Proxy Statement - Edgar
06/06/2005 (09:30 ET) CytoGenix CEO Malcolm Skolnick Discusses HIV Vaccine License and Corporate Strategy with PRBroadcast.com in Online Interview - Business Wire
05/25/2005 (17:04 ET) CYGX: Filed New Form PRE 14A, Preliminary Proxy Statement - Edgar
05/25/2005 (11:45 ET) CYGX: Volume Spike; 45% > 20-adsv, Stock +11.94% - Knobias
05/25/2005 (11:29 ET) CytoGenix Obtains HIV Vaccine License from NIH - Business Wire
05/20/2005 (16:49 ET) CYGX: Filed New Form 10-Q, Quarterly Report - Edgar
05/19/2005 (12:05 ET) CYGX: Volume Spike; 87% > 20-adsv, Stock -7.81% - Knobias
05/18/2005 (12:36 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/18/2005 (12:25 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/17/2005 (11:00 ET) CYGX: Volume Spike; 19% > 20-adsv, Stock +2.31% - Knobias
05/17/2005 (10:00 ET) CytoGenix Launches Innovative Vaccine Program Using Proprietary Cell-Free DNA Production Process - Business Wire
05/16/2005 (16:30 ET) CYGX: Filed New Form NT 10-Q, Quarterly Report to be Filed Late - Edgar
05/16/2005 (13:30 ET) CYGX: Volume Spike; 112% > 20-adsv, Stock +15.25% - Knobias
05/03/2005 (13:18 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/03/2005 (12:39 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/03/2005 (12:06 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
04/20/2005 (10:00 ET) CytoGenix Engages Premier Biopharmaceutical Engineering Firm to Design DNA Production Plant - Business Wire
04/14/2005 (17:01 ET) CYGX: Filed New Form 10KSB, Annual Report - Edgar
04/14/2005 (07:00 ET) CytoGenix First Quarter 2005 Update - Business Wire
04/07/2005 (01:19 ET) Dutton Covered Company Corrects Disclosure Deficiency - Investrend
04/06/2005 (16:57 ET) ADDING and REPLACING CytoGenix Announces New Analyst Report with Speculative Buy Rating - Business Wire
04/06/2005 (01:12 ET) Living Dangerously: Another Dutton Coverage Announced Without Compensation Disclosure - Investrend
06/27/2005 (12:03 ET) Audiostocks.Com Interviews Leading Executives - PrimeZone Media Network
06/21/2005 (10:07 ET) CYGX:Announces Testing of Vaccine Against Smallpox - Knobias
06/21/2005 (10:05 ET) CytoGenix Announces Testing of Synthetic DNA Vaccine Against Smallpox - Business Wire
06/17/2005 (13:28 ET) CYGX: Filed New Form DEF 14A, Definitive Proxy Statement - Edgar
06/06/2005 (09:30 ET) CytoGenix CEO Malcolm Skolnick Discusses HIV Vaccine License and Corporate Strategy with PRBroadcast.com in Online Interview - Business Wire
05/25/2005 (17:04 ET) CYGX: Filed New Form PRE 14A, Preliminary Proxy Statement - Edgar
05/25/2005 (11:45 ET) CYGX: Volume Spike; 45% > 20-adsv, Stock +11.94% - Knobias
05/25/2005 (11:29 ET) CytoGenix Obtains HIV Vaccine License from NIH - Business Wire
05/20/2005 (16:49 ET) CYGX: Filed New Form 10-Q, Quarterly Report - Edgar
05/19/2005 (12:05 ET) CYGX: Volume Spike; 87% > 20-adsv, Stock -7.81% - Knobias
05/18/2005 (12:36 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/18/2005 (12:25 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/17/2005 (11:00 ET) CYGX: Volume Spike; 19% > 20-adsv, Stock +2.31% - Knobias
05/17/2005 (10:00 ET) CytoGenix Launches Innovative Vaccine Program Using Proprietary Cell-Free DNA Production Process - Business Wire
05/16/2005 (16:30 ET) CYGX: Filed New Form NT 10-Q, Quarterly Report to be Filed Late - Edgar
05/16/2005 (13:30 ET) CYGX: Volume Spike; 112% > 20-adsv, Stock +15.25% - Knobias
05/03/2005 (13:18 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/03/2005 (12:39 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
05/03/2005 (12:06 ET) CYGX: New Form 4 Filed, Change in Beneficial Ownership - Edgar
04/20/2005 (10:00 ET) CytoGenix Engages Premier Biopharmaceutical Engineering Firm to Design DNA Production Plant - Business Wire
04/14/2005 (17:01 ET) CYGX: Filed New Form 10KSB, Annual Report - Edgar
04/14/2005 (07:00 ET) CytoGenix First Quarter 2005 Update - Business Wire
04/07/2005 (01:19 ET) Dutton Covered Company Corrects Disclosure Deficiency - Investrend
04/06/2005 (16:57 ET) ADDING and REPLACING CytoGenix Announces New Analyst Report with Speculative Buy Rating - Business Wire
04/06/2005 (01:12 ET) Living Dangerously: Another Dutton Coverage Announced Without Compensation Disclosure - Investrend
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 133 | ||
| 82 | ||
| 52 | ||
| 32 | ||
| 31 | ||
| 27 | ||
| 26 | ||
| 14 | ||
| 13 | ||
| 10 |
| Wertpapier | Beiträge | |
|---|---|---|
| 10 | ||
| 10 | ||
| 10 | ||
| 8 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 7 | ||
| 6 | ||
| 6 |
